Cell Growth Inhibition and Functioning of Human Somatostatin Receptor Type 2 Are Modulated by Receptor Heterodimerization
Open Access
- 1 October 2008
- journal article
- research article
- Published by The Endocrine Society in Molecular Endocrinology
- Vol. 22 (10) , 2278-2292
Abstract
Somatostatin (SST) analogs have been successfully used in the medical treatment of acromegaly, caused by GH hypersecreting pituitary adenomas. Patients on SST analogs rarely develop tachyphylaxis despite years of continuous administration. It has been recently proposed that a functional association between SST receptor (SSTR) subtypes 2 and 5 exists to account for this behavior; however, a physical interaction has yet to be identified. Using both coimmunoprecipitation and photobleaching fluorescence resonance energy transfer microscopy techniques, we determined that SSTR2 and SSTR5 heterodimerize. Surprisingly, selective activation of SSTR2 and not SSTR5, or their costimulation, modulates the association. The SSTR2-selective agonist L-779,976 is more efficacious at inhibiting adenylate cyclase, activating ERK1/2, and inducing the cyclin-dependent kinase inhibitor p27Kip1 in cells expressing both SSTR2 and SSTR5 compared with SSTR2 alone. Furthermore, cell growth inhibition by L-779,976 treatment was markedly extended in coexpressing cells. Trafficking of SSTR2 is also affected upon heterodimerization, an attribute corresponding to modifications in β-arrestin association kinetics. Activation of SSTR2 results in the recruitment and stable association of β-arrestin, followed by receptor internalization and intracellular receptor pooling. In contrast, heterodimerization increases the recycling rate of internalized SSTR2 by destabilizing its interaction with β-arrestin. Given that SST analogs show preferential binding to SSTR2, these data provide a mechanism for their effectiveness in controlling pituitary tumors and the absence of tolerance seen in patients undergoing long-term administration.Keywords
This publication has 64 references indexed in Scilit:
- Ghrelin Amplifies Dopamine Signaling by Cross Talk Involving Formation of Growth Hormone Secretagogue Receptor/Dopamine Receptor Subtype 1 HeterodimersMolecular Endocrinology, 2006
- Heterodimerization of G Protein-Coupled Receptors: Specificity and Functional SignificancePharmacological Reviews, 2005
- A Critical Analysis of Pituitary Tumor Shrinkage during Primary Medical Therapy in AcromegalyThe Journal of Clinical Endocrinology & Metabolism, 2005
- A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimersProceedings of the National Academy of Sciences, 2005
- Concurrent Stimulation of Cannabinoid CB1 and Dopamine D2 Receptors Enhances Heterodimer Formation: A Mechanism for Receptor Cross-Talk?Molecular Pharmacology, 2005
- The Antitumoral Effects of Somatostatin Analog Therapy in AcromegalyThe Journal of Clinical Endocrinology & Metabolism, 2005
- Agonist-dependent Dissociation of Human Somatostatin Receptor 2 DimersJournal of Biological Chemistry, 2004
- Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours.Endocrine-Related Cancer, 2003
- Agonist‐promoted heteromeric oligomerization between adenosine A1 and P2Y1 receptors in living cellsFEBS Letters, 2002
- Mutation and expression analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in pituitary tumorsJournal of Endocrinology, 1998